

*sub cont'd*  
~~101~~ 2

--19. A pharmaceutical composition containing  
 as active ingredient a compound according to claim 4.--;

1                   <sup>9</sup>  
~~--20.~~ A method for inhibiting gastric acid  
 2 secretion by administering to mammals an amount of a  
 3 compound as defined in claim 1 sufficient to inhibit  
 4 gastric acid secretion.--;

1                   <sup>10</sup>  
~~--21.~~ A method for inhibiting gastric acid  
 2 secretion by administering to mammals an amount of a  
 3 compound as defined in claim 2 sufficient to inhibit  
 4 gastric acid secretion.--;

1                   <sup>11</sup>  
~~--22.~~ A method for inhibiting gastric acid  
 2 secretion by administering to mammals an amount of a  
 3 compound as defined in claim 3 sufficient to inhibit  
 4 gastric acid secretion.--;

*cont'd*

1                   <sup>12</sup>  
~~--23.~~ A method for inhibiting gastric acid  
 2 secretion by administering to mammals an amount of a  
 3 compound as defined in claim 4 sufficient to inhibit  
 4 gastric acid secretion.--;

1                   <sup>13</sup>  
~~--24.~~ A method for the treatment of gastro-  
 2 intestinal inflammatory diseases in mammals by administer-  
 3 ing to mammals an amount of a compound as defined in  
 4 claim 1 sufficient to treat gastrointestinal inflammatory  
 5 disease.--;

1                   <sup>14</sup>  
~~--25.~~ A method for the treatment of gastro-  
 2 intestinal inflammatory diseases in mammals by administer-  
 3 ing to mammals an amount of a compound as defined in  
 4 claim 2 sufficient to treat gastrointestinal inflammatory  
 5 disease.--;

BEST AVAILABLE COPY

1           <sup>15</sup>  
--~~26~~. A method for the treatment of gastro-  
2 intestinal inflammatory diseases in mammals by administer-  
3 ing to mammals an amount of a compound as defined in  
4 claim 3 sufficient to treat gastrointestinal inflammatory  
5 disease.--;

1           <sup>16</sup>  
--~~27~~. A method for the treatment of gastro-  
2 intestinal inflammatory diseases in mammals by administer-  
3 ing to mammals an amount of a compound as defined in  
4 claim 4 sufficient to treat gastrointestinal inflammatory  
5 disease.--;

1           <sup>17</sup>  
--~~28~~. A method for providing gastrointestinal  
2 cytoprotective effects in mammals by administering to  
3 mammals an amount of a compound as defined in claim 1  
4 sufficient to provide gastrointestinal cytoprotective  
5 effects.--;

1           <sup>18</sup>  
--~~29~~. A method for providing gastrointestinal  
2 cytoprotective effects in mammals by administering to  
3 mammals an amount of a compound as defined in claim 2  
4 sufficient to provide gastrointestinal cytoprotective  
5 effects.--;

1           <sup>19</sup>  
--~~30~~. A method for providing gastrointestinal  
2 cytoprotective effects in mammals by administering to  
3 mammals an amount of a compound as defined in claim 3  
4 sufficient to provide gastrointestinal cytoprotective  
5 effects.--;

BEST AVAILABLE COPY

1                   <sup>20</sup>  
2                   --31. A method for providing gastrointestinal  
3                   cytoprotective effects in mammals by administering to  
4                   mammals an amount of a compound as defined in claim 4  
5                   sufficient to provide gastrointestinal cytoprotective  
                  effects. *Find*

*cat 8*

Respectfully submitted,

*M. Andrea Ryan*

Allan H. Bonnell  
Patent Office Reg. No. 22,059

M. Andrea Ryan  
Patent Office Reg. No. 28,469

Attorneys for Applicant  
(212) 408-2572

Enclosures

BEST AVAILABLE COPY